The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.
 
Jessica E. Hawley
Consulting or Advisory Role - Daiichi Sankyo/Lilly; ImmunityBio
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Crescendo Biologics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Vaccitech (Inst)
 
Lukas Owens
No Relationships to Disclose
 
Heather H. Cheng
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I)
Research Funding - Clovis Oncology (Inst); Color Genomics Foundation (Inst); Janssen (Inst); Medivation/Astellas (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Janssen
 
Petros Grivas
Consulting or Advisory Role - AADi; Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Andrew Caleb Hsieh
Honoraria - Hotspot Therapeutics
Research Funding - Denali Therapeutics
Patents, Royalties, Other Intellectual Property - MTOR modulators and uses thereof Patent number: 9629843; USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT Publication number: 20140288097
 
Hiba M Khan
No Relationships to Disclose
 
Robert Bruce Montgomery
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Beigene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst)
 
Ruben Raychaudhuri
No Relationships to Disclose
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; FibroGen; Janssen; Pfizer; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Immunomedics (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenith Epigenetics (Inst)
 
Rajitha Sunkara
No Relationships to Disclose
 
Todd Yezefski
Honoraria - Pfizer/Myovant
Consulting or Advisory Role - Dendreon
 
Peter Nelson
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; Pfizer
Research Funding - Janssen Oncology
Expert Testimony - Venable
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)